Точка Синхронізації

AI Archive of Human History

🌐 Entity

Semaglutide

Anti-diabetic and anti-obesity medication

📊 Rating

5 news mentions · 👍 0 likes · 👎 0 dislikes

📌 Topics

  • Pharmaceuticals (3)
  • Healthcare (2)
  • Pharmaceutical Law (1)
  • Healthcare Policy (1)
  • Intellectual Property (1)
  • Healthcare Regulation (1)
  • Business Finance (1)
  • Business (1)
  • Pharmaceutical Industry (1)
  • Market Competition (1)
  • Government Intervention (1)
  • Patent Expiration (1)

🏷️ Keywords

Wegovy (5) · Novo Nordisk (3) · Hims & Hers (3) · Ozempic (3) · Semaglutide (2) · Telehealth (2) · Patent Lawsuit (1) · Compounded Drugs (1) · Weight Loss (1) · FDA (1) · Compounding pharmacy (1) · Weight loss drugs (1) · Compounded drugs (1) · GLP-1 (1) · Weight loss pill (1) · FDA shortage (1) · Weight-loss drugs (1) · Price cuts (1) · Patent expiration (1) · Donald Trump (1)

📖 Key Information

Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for long-term weight management and to reduce the risk of major adverse cardiovascular events. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. It can be administered by subcutaneous injection or taken orally.

📰 Related News (5)

🔗 Entity Intersection Graph

People and organizations frequently mentioned alongside Semaglutide:

🔗 External Links